Given that ITGA3 levels remain primarily unaffected by tumor progression, it could serve as a dependable biomarker for prognosis, particularly within specific BC subtypes, such as ER-positive, Luminal A, and Luminal B subtypes. Here, ESR1 is linked to neoplasm.